|
|
'Govt policy would succeed if generic drug quality improves'
|
|
|
|
Top Stories |
|
|
|
|
SME Times News Bureau | 25 Apr, 2017
The Centre's steps to make
doctors prescribe drugs by their generic names and not by their brand
names may not have material impact without steps for improving the
quality standards for drugs, investment banking firm Jefferies has said.
In
a report issued on Sunday, Jefferies said: "In our view, without steps
for improving quality standards for drugs available in the market, the
move will not have much material impact and will shift power from
doctors to pharmacists."
According to Jefferies, transition to generics is a long term aim where the first step needs to be quality.
The
push towards generic drugs began with Prime Minister Narendra Modi
declaring that the government will bring a legal framework to get
doctors to prescribe generic names, said Jefferies.
Soon after
the Medical Council of India (MCI) directed doctors to write generic
names in prescriptions or face disciplinary action.
According to
Jefferies, the push to get the doctors to prescribe generic names, is
one of the many steps the government has been taking to reduce medical
costs in India.
The key ones has been 1) expansion of National
list of Essential Medicines (NLEM) bringing them under price cap, 2)
push by the government to increase awareness of generic drug prices and
3) increase access through Jan Aushadhi programme.
"A shift to a
generic-generic model (similar to US) from the branded generic model
currently in India, requires confidence among doctors, pharmacists and
patients on the quality of drugs available in market," Jefferies said.
The
key focus of the government then needs to be towards strengthening and
empowering the regulator. It also needs to improve and standardise the
drug approval process in India, the report added.
"Without
quality assurance, move just shifts power to pharmacy - While the push
to generic prescription is a positive step for the consumer, without
quality assurance and awareness, we believe branded generics will still
retain majority share," Jefferies said.
According to the report, prescriptions by generic names will shift the brand selection power to pharmacist.
"The
focus of companies, in the current environment, will then shift to
pharmacists for marketing their drugs. At the pharmacy level,
generic-generic drugs have much higher margins than branded drugs but
the lower retail price and lack of quality assurance will keep branded
drugs the preferred pick for pharmacists to dispense," Jefferies said.
According to Jefferies, a move towards a generic-generic market is negative for the Indian pharmaceutical companies.
"This
move, though, is a long term target in our view. It will require
multiple steps including 1) strengthening the drug approval process, 2)
strengthening the drug regulator, 3) increased inspection of drug
facilities, 4) increased awareness of generic drugs and their quality
and 5) rationalising the fixed dosage combination drugs," Jefferies
said.
|
|
|
|
|
|
|
|
|
|
|
|
|
Customs Exchange Rates |
Currency |
Import |
Export |
US Dollar
|
66.20
|
64.50 |
UK Pound
|
87.50
|
84.65 |
Euro
|
78.25
|
75.65 |
Japanese
Yen |
58.85 |
56.85 |
As on 13 Aug, 2022 |
|
|
Daily Poll |
|
|
PM Modi's recent US visit to redefine India-US bilateral relations |
|
|
|
|
|
Commented Stories |
|
|
|
|
|
|
|
|